Hao Hao

Hao Hao


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2024 in Inflammation Research
Verified
Journal Article
Closed access
PDF file
JDJinyan Dong
Jinyan Dong
WLWeihong Liu
Weihong Liu
WLWenli Liu
Wenli Liu
YWYuqi Wen
Yuqi Wen
QLQingkuo Liu
Qingkuo Liu
HHHao Hao
Hao Hao

22 July 2023 in Toxicology and Applied Pharmacology
Verified
Journal Article
Closed access
YQYiheng Quan
Yiheng Quan
PSPengchao Su
Pengchao Su
CSChenhong Shangguan
Chenhong Shangguan
HHHao Hao
Hao Hao
LYLijuan Yue
Lijuan Yue
CCChen Chen
Chen Chen

17 August 2024 in Inflammation Research
Verified
Journal Article
Closed access
PDF file
YWYuqi Wen
Yuqi Wen
YLYang Liu
Yang Liu
WLWeihong Liu
Weihong Liu
WLWenli Liu
Wenli Liu
JDJinyan Dong
Jinyan Dong
HHHao Hao
Hao Hao

4 October 2023 in Immunity, Inflammation and Disease
Verified
Journal Article
Open access
YWYuqi Wen
Yuqi Wen
YLYang Liu
Yang Liu
WLWeihong Liu
Weihong Liu
WLWenli Liu
Wenli Liu
JDJinyan Dong
Jinyan Dong
HRHONGSHENG Ren
HONGSHENG Ren
Sepsis is an uncontrolled host response to infection, resulting in a clinical syndrome involving multiple organ dysfunctions. Cardiac damage is the most common organ damage in sepsis. Uncontrolled inflammatory response is an important mechanism in the pathogenesis of septic cardiomyopathy (SCM). NLRP3 inflammasome promotes inflammatory response by controlling the activation of caspase‐1 and the release of pro‐inflammatory cytokines interleukin IL‐1β and IL‐18. The role of NLRP3 inflammasome has received increasing attention, but its activation mechanism and regulation of inflammation in SCM remain to be investigated.

21 May 2021 in Virology Journal
Verified
Journal Article
Open access
PDF file
XHXiao Hou
Xiao Hou
LTLi Tian
Li Tian
LZLei Zhou
Lei Zhou
XJXinhua Jia
Xinhua Jia
LKLi Kong
Li Kong
XDXiaobin Dong
Xiaobin Dong
Objective: Coronavirus disease 2019 (COVID-19) is a major challenge facing the world. Certain guidelines issued by National Health Commission of the People's Repubilic of China recommend intravenous immunoglobulin (IVIG) for adjuvant treatment of COVID-19. However, there is a lack of clinical evidence to support the use of IVIG. Methods: This single-center retrospective cohort study included all adult patients with laboratory-confirmed severe COVID-19 in the Respiratory and Critical Care Unit of Dabie Mountain Regional Medical Center, China. Patient information, including demographic data, laboratory indicators, the use of glucocorticoids and IVIG, hospital mortality, the application of mechanical ventilation, and the length of hospital stay was collected. The primary outcome was the composite end point, including death and the use of mechanical ventilation. The secondary outcome was the length of hospital stay. Results: Of the 285 patients with confirmed COVID-19, 113 severely ill patients were included in this study. Compared to the non-IVIG group, more patients in the IVIG group reached the composite end point [12 (25.5%) vs 5 (7.6%), P = 0.008] and had longer hospital stay periods [23.0 (19.0–31.0) vs 16.0 (13.8–22.0), P < 0.001]. After adjusting for confounding factors, differences in primary outcomes between the two groups were not statistically significant (P = 0.167), however, patients in the IVIG group had longer hospital stay periods (P = 0.041). Conclusion: Adjuvant therapy with IVIG did not improve in-hospital mortality rates or the need for mechanical ventilation in severe COVID-19 patients. Our study does not support the use of immunoglobulin in patients with severe COVID-19 patients.

1 April 2023 in Journal of Inflammation Research
Verified
Journal Article
Open access
PDF file
JDJin-Yan Dong
Jin-Yan Dong
HYHong-Lin Yin
Hong-Lin Yin
HHHao Hao
Hao Hao
YLYang Liu
Yang Liu
Autophagy is a highly conserved process that maintains cell stability in eukaryotes, participates in the turnover of intracellular substances to maintain cell function, helps to resist pathogen invasion, and improves cell tolerance to environmental changes. Autophagy has been observed in many diseases, and the symptoms of these diseases are significantly improved by regulating autophagy. Autophagy is also involved in the development of lung diseases. Studies have shown that autophagy may play a beneficial or harmful role in acute lung injury (ALI), and ALI has been treated with traditional Chinese medicine designed to promote or inhibit autophagy. In this paper, the molecular mechanism and common pathways regulating autophagy and the relationship between autophagy and ALI are introduced, and the active ingredients of traditional Chinese medicine that improve ALI symptoms by regulating autophagy are summarized.